. . "357-70-0"@en . . . . . "Galantamine"@en . "Galanthamine"@en . . "A benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Galantamine is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimer's disease and other central nervous system disorders. [PubChem]"@en . "Galantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine's proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors."@en . . . . . "(-)-Galanthamine"@en . "Humans and other mammals"@en . . . . . . . . . . . "* 175 L"@en . . "approved"@en . . . . . . . . "Take with food."@en . . . "* 300 mL/min [After IV. or oral administration]"@en . . "7 hours"@en . . . . . . . . " "@en . "Vijaya Bolugoddu, Sanjay Shukla, Mukunda Jambula, Rajeshwar Sagyam, Ramchandra Pingili, Ananda Thirunavakarasu, \"Preparation of (-)-galantamine hydrobromide.\" U.S. Patent US20060009640, issued January 12, 2006."@en . . . . . "Galantamine is metabolized by hepatic cytochrome P450 enzymes, glucuronidated, and excreted unchanged in the urine."@en . . "# Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11129124 # Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10606746 # Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11172080 # Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16437532# Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12177686 # Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12137632# Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11129124"@en . . " "@en . . . . . . "18%"@en . . . . . . . . . . . . . . . . . . . . . "For the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease."@en . . . . . . . . . . . . . . . . . . . . . . "LD₅₀=75 mg/kg (rat)"@en . . . . . . . . . . . . . .